SEOUL -- Vect-Horus, a French biotech company that develops peptide-based vectors facilitating the drug delivery or imaging agents into the brain, will work with MDimune, a South Korean provider of cancer therapeutics, to jointly develop a drug delivery system for central nervous system diseases.
Vect-Horus designs and develops vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs. MDimune utilizes a platform that leverages cell-derived vesicles obtained from various human cells to achieve target-specific drug delivery and strive to expand its technology to address a wide range of debilitating diseases and neurodegenerative
Under a joint R&D contract, the two companies aim to develop a next-generation drug delivery system, which can be effective in the brain with only a small amount of drugs, by grafting Vect-Horus' technology onto the surface of MDimune's cell-derived vesicle
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.